A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs IPI 549 (Primary) ; Nivolumab
  • Indications Breast cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2017 According to an Infinity Pharmaceuticals media release, company expects to complete the combination dose escalation and initiate the combination expansion cohorts by the end of 2017. two additional cohorts arae adding to the combination expansion component of the study, one in mesothelioma and one in adrenocortical carcinoma.
    • 10 Nov 2017 Data from the monotherapy dose-escalation component of this study presented in an Infinity Pharmaceuticals Media Release.
    • 10 Nov 2017 According to an Infinity Pharmaceuticals media release, data from the recently completed monotherapy dose-escalation component of this study will be presented at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top